Lack of Interleukin-5 Production by T-Lymphocytes Isolated from Fibromyalgia Patients and Normal Controls After Being Cultured with 1,1′-Ethylidenebis Tryptophan, a Suspected Causal Contaminant of Eosinophilia-Myalgia Syndrome

REFERENCES

• Dinerman H, Goldenberg D L, Felson D T. A prospective evaluation of 118 patients with the fibromyalgia syndrome; prevalence of Raynaud's phenomenon, sicca symptoms, ANA, low complement, and Ig deposition at the dermal-epidermal junction. J Rheumatol 1986; 13(2)368–373
   PubMedGoogle Scholar
• Bennett R M, Clark S R, Campbell S M, Ingram S B, Burckhardt C S, Nelson D L, Porter J M. Symptoms of Raynaud's syndrome in patients with fibromyalgia. A study utilizing the Nielson test, digital photoplethsmography, and measurements of platelet alpha 2-adrenergic receptors. Arthritis Rheum 1991; 34(3)264–269
   PubMedGoogle Scholar
• Lindberg D, Ahlfors U G, Dencker S J, Fruensgaard K, Hansten S, Jensen K, Ose E, Pihkanen T A. Symptom reduction in depression after treatment with L-tryptophan or imipramine. Item analysis of Hamilton rating scale for depression. Acta Psychiatr Scand 1979; 60(3)287–294
   PubMedGoogle Scholar
• Thomson J, Rankin H, Ashcroft G W, Yates C M, McQueen J K, Cummings S W. The treatment of depression in general practice: a comparison of L-tryptophan, amitriptyline, and a combination of L-tyrptophan and amitriptyline with placebo. Psychol Med 1982; 12(4)741–751
   PubMedGoogle Scholar
• Zangrilli J G, Maycno A N, Vining V, Varga J. 1,1′-Ethlidenebis[L-tryptophan], an impurity in L-tryptophan associated with eosinophilia-myalgia syndrome, stimulates type I collagen gene expression in human fibroblasts in vitro. Biochem Mol Biol Int 1995; 37(5)925–933
   PubMedGoogle Scholar
• Takagi H, Ochoa M S, Zhou L, Helfman T, Murata H, Falanga V. Enhanced collagen synthesis and transcription by peak E, a contaminant of L-tryptophan preparations associated with the eosinophilia myalgia syndrome epidemic. J Clin Invest 1995; 96(5)2120–2125
   PubMedGoogle Scholar
• Varga J, Peltonen J, Uitto J, Jimenez S. Development of diffuse fasciitis with eosinophilia during L-tryptophan treatment: Demonstration of elevated type I collagen gene expression in affected tissues. Ann Intern Med 1990; 112: 344–351
   PubMedGoogle Scholar
• Moldofsky H, Warsh J J. Plasma tryptophan and musculoskeletal pain in non-articular rheumatism (“fibrositis syndrome”). Pain 1978; 5: 65–71
   PubMed Web of Science ®Google Scholar
• Russell I J, Michalek J E, Vipraio G A, Fletcher E M, Wall K. Serum amino acids in fibrositis/fibromyalgia syndrome. J Rheumatol 1989; 16(suppl 19)153–163
   Google Scholar
• Yunus M B, Dailey J W, Aldag J C, Masi A T, Jobe P C. Plasma tryptophan and other amino acids in primary fibromyalgia: a controlled study. J Rheumatol 1992; 19(1)90–94
   PubMedGoogle Scholar
• Goldenberg D, Mayskiy M, Mossey C, Ruthazer R, Schmid C. A randomized, double-blind crossover trial of fluoxetine and amitriptyline in the treatment of fibromyalgia. Arthritis Rheum 1996; 39(11)1852–1859
   PubMed Web of Science ®Google Scholar
• Russell I J, Michalek J E, Vipraio G A, Fletcher E M, Javors M A, Bowden C A. Platelet 3H-imiprimamine uptake receptor density and serum serotonin levels in patients with fibromyalgia/fibrositis syndrome. J Rheumatol 1992; 19(1)104–109
   PubMed Web of Science ®Google Scholar
• Hudson J I, Pope H G, Jr., Daniels S R, Horwitz R I, Goldenberg D L. Fibromyalgia and eosinophilia-myalgia syndrome. J Musculoske Pain 1995; 3(1)63–75
   Google Scholar
• Hudson J I, Daniels S R, Horwitz R I. Eosinophilia-myalgia syndrome or fibromyalgia with eosinophilia? (letter). JAMA 1993; 269(24)3108
   PubMedGoogle Scholar
• Daniels S R, Hudson J I, Horwitz R I. Epidemiology of potential association between L-tryptophan ingestion and eosinophilia-myalgia syndrome. J Clin Epidemiol 1995; 48(12)1413–1427
   PubMedGoogle Scholar
• Clutterbuck E J, Sanderson C. Regulation of human eosinophil precursor production by cytokines: a comparison of recombinant human interleukin-1 (rhIL-1), rhIL-3, rhIL-5, rhIL-6 and rh granulocyte-macrophage colony stimulating factor. Blood 1990; 75: 1774–1779
   PubMed Web of Science ®Google Scholar
• Yamaoka K A, Miyasaka N, Kashiwazaki S. L-tryptophan contaminant “Peak E” and interleukin-5 production from T cells. Lancet 1991; 338: 1468
   PubMedGoogle Scholar
• Yamaoka K A, Miyasaka N, Inuo G, Saito I, Kolb J, Fujita K, Kashiwazaki S. 1,1′-Ethylidenebis (tryptophan) (Peak E) induces functional activation of human eosinophils and interleukin 5 production from T-lymphocytes: association of eosinophilia-myalgia syndrome with a L-tryptophan contaminant. J Clin Immunol 1994; 14(1)50–60
   PubMedGoogle Scholar
• Klein R, Berg P A. A comparative study on antibodies to nucleoli and 5-hydroxytryptamine in patients with fibromyalgia syndrome and tryptophan and tryptophan-induced eosinophilia-myalgia syndrome. Clin Investig 1994; 72(7)541–549
   PubMedGoogle Scholar
• Wolfe F, Smythe H A, Yunus M B, Bennett R M, Bombardier C, Goldenberg D L, Tugwell P, Campbell S M, Abeles M, Clark P, et al. The American College of Rheumatology 1990 Criteria for the Classification of Fibromyalgia. Arthritis Rheum 1990; 33(2)160–172
   PubMed Web of Science ®Google Scholar
• Kita H, Mayeno A N, Weyand C M, Goronzy J J, Weiler D A, Lundy S K, Abrams J SS, Gleich G J. Eosinophil-active cytokine from mononuclear cells cultured with L-tryptophan products: an unexpected consequence of endotoxin contamination. J Allergy Clin Immunol 1995; 95: 1261–1267
   PubMedGoogle Scholar
• Haas W, Pereira P, Tonegawa S. Gamma/Delta Cells. Annu Review Immunol 1993; 11: 637–85
   PubMed Web of Science ®Google Scholar
• Tanaka Y, Morita C T, Tanaka Y, Nieves E, Brenner M B, Bloom B R. Natural and synthetic non-peptides recognized by human gamma/delta cells. Nature 1995; 375: 155–158
   PubMed Web of Science ®Google Scholar
• Ebisawa M, Yamada T, Bickel C, Klunk D, Schleimer R P. Eosinophil transendothelial migration induced by cytokines. III. Effect of the chemokine RANTES. J Immunol 1994; 153(5)2153–2160
   PubMedGoogle Scholar